Tilray Eyes $45B European Cannabis Market, But Profits Still Hazy
-
Tilray sees a $45B opportunity in the European medical cannabis market, especially with recent German reforms that expand access.
-
Tilray already has a strong presence in Europe through its distribution arm, which is a significant revenue driver. The German reforms could double its opportunity there.
-
While the expanded access in Germany presents a revenue growth opportunity for Tilray, profitability has been declining recently. Investors want to see profits improve.
-
Realizing the full $45B European opportunity could take over a decade as more countries would need to reform medical cannabis laws.
-
Despite positive developments, Tilray remains a high-risk investment. The stock is down 40% in the past year and better suited for a watchlist than a portfolio currently.